Takeaways
- Lentiviral gene therapy for ADA-SCID demonstrated 100% overall survival and 95% event-free survival, with durable engraftment and no late treatment failures beyond 1 year.
- Immune reconstitution remained robust long term, with sustained…
Long-term outcomes of lentiviral gene therapy for ADA-deficient severe combined immunodeficiency
